The hypoglycemic effects of Juglans regia L. internal septum in type 2 diabetic patients: A double-blind, randomized, placebo-controlled clinical trial

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Fatemeh Afra, Arman Zargaran, Nooshin Shirzad, Mahboobeh Hemmatabadi, Mahbube Ebrahimpur, Mehrdad Karimi, Mahnaz Khanavi, Mehrzad Mirshekari, Soha Namazi
{"title":"The hypoglycemic effects of <i>Juglans regia</i> L. internal septum in type 2 diabetic patients: A double-blind, randomized, placebo-controlled clinical trial","authors":"Fatemeh Afra, Arman Zargaran, Nooshin Shirzad, Mahboobeh Hemmatabadi, Mahbube Ebrahimpur, Mehrdad Karimi, Mahnaz Khanavi, Mehrzad Mirshekari, Soha Namazi","doi":"10.34172/jcvtr.2023.31835","DOIUrl":null,"url":null,"abstract":"Introduction: The internal septum of J.regia is traditionally used to control diabetes, and its effectiveness has been shown in animal studies. Accordingly, human clinical trials are needed to confirm its effectiveness on hemoglobin A1c (HbA1c), fasting blood sugar (FBS), blood insulin level, and insulin resistance as a complementary for better control of type 2 diabetes. Methods: This study was a randomized, double-blinded, controlled trial. The lyophilized powder of extract of the internal septum of J.regia was used to fill the capsules. Sixty type 2 diabetic patients were randomly divided into two groups. 500 mg capsules three times daily before meal was added to their routine drug regimen, and HbA1c, FBS, and blood insulin level were checked at the baseline and after three months. Results: Sixty patients completed the study. The mean(±SD) age of patients was 49.1(10.2) and 50.9(12.7) years in the placebo and J.regia groups, respectively. We observed that J.regia internal septum increases the level of HbA1c by about 0.02 units, but this effect was not significant (MD=0.02,95%CI=-0.36 to 0.40, P=0.93). Regarding the impact of capsules on insulin level, it seems that J.regia-containing capsules can raise insulin level by one unit. However, it was not significant (MD=1.01,95%CI=-0.86 to 2.88, P=0.28). As for FBS, it can cause a decrease of four units, but this effect is also not significant (MD=-3.98,95%CI=-18.33 to 10.37, P=0.58). Conclusion: Based on our study, the internal septum of J.regia has no significant effect on HbA1c, FBS, and insulin resistance. Moreover, no specific adverse reaction was observed in any of the patients.","PeriodicalId":15207,"journal":{"name":"Journal of Cardiovascular and Thoracic Research","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular and Thoracic Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jcvtr.2023.31835","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The internal septum of J.regia is traditionally used to control diabetes, and its effectiveness has been shown in animal studies. Accordingly, human clinical trials are needed to confirm its effectiveness on hemoglobin A1c (HbA1c), fasting blood sugar (FBS), blood insulin level, and insulin resistance as a complementary for better control of type 2 diabetes. Methods: This study was a randomized, double-blinded, controlled trial. The lyophilized powder of extract of the internal septum of J.regia was used to fill the capsules. Sixty type 2 diabetic patients were randomly divided into two groups. 500 mg capsules three times daily before meal was added to their routine drug regimen, and HbA1c, FBS, and blood insulin level were checked at the baseline and after three months. Results: Sixty patients completed the study. The mean(±SD) age of patients was 49.1(10.2) and 50.9(12.7) years in the placebo and J.regia groups, respectively. We observed that J.regia internal septum increases the level of HbA1c by about 0.02 units, but this effect was not significant (MD=0.02,95%CI=-0.36 to 0.40, P=0.93). Regarding the impact of capsules on insulin level, it seems that J.regia-containing capsules can raise insulin level by one unit. However, it was not significant (MD=1.01,95%CI=-0.86 to 2.88, P=0.28). As for FBS, it can cause a decrease of four units, but this effect is also not significant (MD=-3.98,95%CI=-18.33 to 10.37, P=0.58). Conclusion: Based on our study, the internal septum of J.regia has no significant effect on HbA1c, FBS, and insulin resistance. Moreover, no specific adverse reaction was observed in any of the patients.
王核桃内隔对2型糖尿病患者的降糖作用:一项双盲、随机、安慰剂对照临床试验
王参的内隔传统上用于控制糖尿病,其有效性已在动物研究中得到证实。因此,需要进行人体临床试验,以证实其对血红蛋白A1c (HbA1c)、空腹血糖(FBS)、血胰岛素水平和胰岛素抵抗的有效性,作为更好地控制2型糖尿病的补充。方法:采用随机、双盲、对照试验。采用王参内隔提取物冻干粉填充胶囊。60例2型糖尿病患者随机分为两组。在常规用药方案中添加500 mg胶囊,每日3次,餐前服用,并在基线和3个月后检测HbA1c、FBS和血胰岛素水平。结果:60例患者完成了研究。安慰剂组和王参组患者的平均(±SD)年龄分别为49.1(10.2)岁和50.9(12.7)岁。我们观察到王菊内隔可使HbA1c升高约0.02个单位,但效果不显著(MD=0.02,95%CI=-0.36 ~ 0.40, P=0.93)。关于胶囊对胰岛素水平的影响,含有王参的胶囊似乎可以使胰岛素水平提高一个单位。但差异无统计学意义(MD=1.01,95%CI=-0.86 ~ 2.88, P=0.28)。FBS可以导致4个单位的下降,但这种影响也不显著(MD=-3.98,95%CI=-18.33 ~ 10.37, P=0.58)。结论:根据我们的研究,王菊内隔对HbA1c、FBS和胰岛素抵抗无显著影响。此外,所有患者均未观察到特异性不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cardiovascular and Thoracic Research
Journal of Cardiovascular and Thoracic Research CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.00
自引率
0.00%
发文量
22
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信